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ABSTRACT
BRAF and RAS are the most frequently mutated mitogen-activated protein 
kinase (MAPK) genes in melanoma. Binimetinib is a highly selective MAPK kinase 
(MEK) 1/2 inhibitor with clinical antitumor activity in NRAS- and BRAFV600-mutant 
melanoma. We performed a nonrandomized, open-label phase II study, where 183 
metastatic melanoma patients received binimetinib 45 mg / 60 mg twice-daily (BRAF 
arms), or binimetinib 45 mg twice-daily (NRAS arm). Biomarker analyses were 
prespecified as secondary and exploratory objectives. Here we report the extent of 
MAPK pathway inhibition by binimetinib, genetic pathway alterations of interest, 
and potential predictive markers for binimetinib efficacy. Twenty-five fresh pre- and 
post-dose tumor sample pairs were collected for biomarker analyses, which included 
assessment of binimetinib on MEK/MAPK signaling by pharmacodynamic analysis 
of pERK and DUSP6 expression in pre- vs post-dose tumor biopsies; identification 
of pERK and DUSP6 expression/efficacy correlations; assessment of baseline tumor 
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INTRODUCTION
The MAPK signaling pathway (i.e., RAS-RAF-
MEK-ERK pathway) regulates cellular proliferation, 
survival, and differentiation and contributes to the 
pathogenesis of melanoma [1]. Multiple genetic changes 
can lead to hyperactivation of this pathway, and are 
involved in the pathogenesis of various solid tumor types, 
including melanoma and thyroid, colorectal, and ovarian 
cancer [2–5]. Constitutive MAPK pathway activation 
in cancer can occur through several mechanisms, most 
frequently via mutations in BRAF or RAS. Activating NRAS 
and BRAF mutations are present in approximately 20% 
[6, 7] and 50% [6, 8] of primary cutaneous melanomas, 
respectively.
A number of therapies that directly target the 
MAPK pathway have been approved for BRAF-mutated 
melanoma, including the BRAFV600- specific inhibitors 
vemurafenib (single agent), and dabrafenib (single 
agent or in combination with trametinib), and mitogen-
activated protein kinase (MEK) inhibitors trametinib 
(single agent or in combination with dabrafenib) and 
cobimetinib (in combination with vemurafenib) [9–15]. 
The combination of BRAF and MEK inhibitor therapies 
has shown significantly improved benefit over BRAF 
inhibitor monotherapy in phase III clinical trials [16–
18]. In addition to the nonspecific immunotherapies, 
three immune checkpoint modulators, ipilimumab (anti-
cytotoxic T-lymphocyte associated antigen 4 [CTLA-4]), 
nivolumab (anti–programmed cell death protein 1 [PD-1]), 
and pembrolizumab (anti–PD-1), have been approved for 
the treatment of melanoma [19].
Therapies targeting either mutated BRAF or NRAS 
alone can encounter a number of challenges, including 
resistance to BRAF inhibitors, which occurs frequently, 
mostly through reactivation of the MAPK pathway; 
common paths to resistance include BRAF amplification 
or alternative splicing and mutations in RAS, MAP2K1, 
and CDKN2A [20, 21], among other mechanisms. 
In contrast to BRAF-mutated melanoma, no 
approved targeted therapies exist for NRAS-mutated 
melanoma, but positive phase III data on PFS have been 
reported for a study comparing the efficacy of binimetinib 
(MEK162) versus dacarbazine in unresectable or 
metastatic NRAS-mutated melanoma (NEMO study) 
[22]. Binimetinib is an oral, selective, ATP-uncompetitive 
inhibitor of MEK 1 and MEK 2 [23].
Binimetinib has shown promising results in BRAF-
mutated melanoma, both alone [24] and in combination 
[25]. In addition, preclinical MEK inhibitor activity has 
been shown in BRAF-mutated melanoma [26]. The safety 
profile of binimetinib and preliminary signs of antitumor 
activity were shown in a phase I trial in patients with 
advanced solid tumors [27, 28]. This open-label phase 
II study assessed the use of binimetinib in patients with 
BRAFV600- or NRAS-mutated advanced melanoma. The 
efficacy and safety results from an earlier data cut-off of 
February 29, 2012 (smaller subgroups of patients with 
NRAS- or BRAF-mutated melanoma) have been previously 
reported [24]. No patients had a complete response, and 
6 of 30 patients (20%) with NRAS-mutated melanoma 
(3 confirmed) and 8 of 41 patients (20%) with BRAF-
mutated melanoma (2 confirmed) had a partial response. 
Binimetinib was the first targeted therapy to show activity 
in patients with NRAS-mutated melanoma. 
In this study (NCT01320085), biomarker data 
from binimetinib-treated patients with NRAS- and 
BRAF-mutated melanoma were analysed as prespecified 
secondary and exploratory objectives to investigate the 
extent of MAPK pathway inhibition and further genetic 
pathway alterations, in order to find potential predictive 
markers of response to binimetinib. Among others, dual-
specificity phosphatase 6 (DUSP6) and phosphorylated 
extracellular signal-regulated kinase (pERK) are known/
predicted biomarkers of MAPK inhibition and could 
potentially predict the extent of response to treatment with 
binimetinib [20, 29]. 
RESULTS
Patient disposition and characteristics
At the trial data cut-off date (7 January 2014), a 
total of 183 patients were enrolled. Sixty-six patients with 
molecular status; and exploration of potential predictive biomarkers of efficacy of 
binimetinib. The postbaseline pERK and DUSP6 expression decreased across all arms; 
no association between reduced pERK or DUSP6 levels with clinical efficacy was 
observed. Genetic aberrations were similar to previously reported data on clinical 
melanoma samples. Genetic pathway alterations occurred predominantly within 
CDKN2A/B, PTEN, and TRRAP (BRAF-mutation) and CDKN2A/B, TP53, and NOTCH2 
(NRAS-mutation). Several patients with BRAF mutations had amplification of genes on 
chromosome 7q; these patients tended to have shorter progression-free survival than 
other patients with BRAF-mutant melanoma. Further analysis of genetic alterations, 
including amplifications of growth factor genes, will determine utility as biomarkers 
for efficacy. 
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BRAF mutations were treated: 41 received binimetinib 
45 mg twice daily (BID), and 25 received binimetinib 60 
mg BID (subsequently reduced to 45 mg BID). A total of 
117 patients with NRAS mutations received binimetinib 
45 mg BID (Table 1). Patient demographics and disease 
characteristics are shown in Supplementary Table 1.
Efficacy and safety analysis
Efficacy and safety results for this study have been 
previously reported for the BRAF- and NRAS-mutated 
arms for two data cut-off points, 29 February 2012 [24] 
and 7 January 2014 [31]. Biomarker results presented 
herein are derived from the later cut-off date. 
Biomarker analysis
Biomarkers were analyzed to evaluate MAPK 
pathway inhibition and analysis was undertaken to evaluate 
on-treatment biomarker expression and frequency of tumor 
genetic alterations at baseline. Results were compared 
against melanoma cases in The Cancer Genome Atlas 
(TCGA) database and in the context of clinical outcomes, 
where appropriate. Twenty-five fresh, paired (baseline and 
on Cycle 1, Day 15) tumor samples were collected for 
pharmacodynamic biomarker analysis. Fifteen pairs were 
evaluable for pERK analysis (three pairs in the BRAF-
mutated 45 mg subgroup; four and eight pairs, respectively, 
in the BRAF-mutated 60 mg and NRAS-mutated arms). 
Fourteen pairs were evaluable for DUSP6 analysis (three 
pairs each in the BRAF-mutated 45 mg and 60 mg arms 
and eight pairs in the NRAS-mutated arm).
Pharmacodynamic analysis of postbaseline pERK 
and DUSP6 expression in patients with BRAF and NRAS 
mutations showed MAPK pathway inhibition (Figure 1). 
Decreased postbaseline cytoplasmic and nuclear pERK 
expression was observed in 11 of 15 and in 9 of 15 
paired samples, respectively, and decreased total DUSP6 
Figure 1: Change from baseline in pERK and DUSP6 expression in patients with (A) BRAF or (B) NRAS mutation and correlation with 
best overall response. Single dots represent unpaired biopsies. BOR, best overall response; Cq, quantification cycle; PD, progressive 
disease; PR, partial response; SD, stable disease; UNK, unknown. 
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Table 1: Patient disposition
BRAF-mutant NRAS-mutant All patients
Binimetinib
45 mg
(n = 41)
Binimetinib
60 mg
(n = 25)
Binimetinib
45 mg
(n = 117)
N = 183
Patients treated, n (%)
Treatment discontinued 41 (100) 23 (92.0) 104 (88.9) 168 (91.8)
Treatment ongoinga 0 2 (8.0) 13 (11.1) 15 (8.2)
Primary reason for end of 
treatment, n (%)
Adverse event(s)b 12 (29.3) 5 (20.0) 14 (12.0) 31 (16.9)
Patient withdrew consent 2 (4.9) 1 (4.0) 4 (3.4) 7 (3.8)
Disease progression 26 (63.4) 16 (64.0) 86 (73.5) 128 (69.9)
Protocol deviation 1 (2.4) 1 (4.0) 0 2 (1.1)
Duration of exposure, 
median (range), weeks
9.6 (1.1–26.6) 8.0 (2.0–102) 15.9 (0.3–87.9) 11.6 (0.3–102.0)
BRAF mutation status, n (%)c
None (no wild-type 
mutation detected)
0 0 3 (2.6)
V600E 34 (82.9) 19 (76.0) 0
V600K 5 (12.2) 1 (4.0) 0 –
Unknown mutation 1 (2.4)f 2 (8.0)f 0
Other (mutations other than 
V600E/K)d
1 (2.4)g 0 0
Missing (no V600 BRAF 
mutation data)e
0 3 (12.0)f 114 (97.4)
NRAS mutation status, n (%)c
None (no mutation detected) 0 5 (20.0) 4 (3.4)h
Q61 0 0 100 (85.5)
G12/13 0 0 2 (1.7) –
Unknown mutationc 1 (2.4) 0 1 (0.9)i
Missing (no NRAS mutation 
data)
40 (97.6) 20 (80.0) 10 (8.5)j
Clinical activityk [24] (n = 35) NR (n = 28)
DCR, n (%) 21 (60) NR 19 (68)
aTreatment ongoing at the time of the cut-off (Jan 7, 2014)
bIncludes fatal case with liver failure in the BRAF-mutated 60-mg treatment group;
cAny other mutation not known; known mutation includes all Q61, A59T, A11T, G12V, G13R; 
dAny other known mutation (L597, D594, G606, K60); 
eAnalysis results are missing; 
fV600E according to local laboratory; 
gV600R according to local laboratory; 
hThree Q61R (1 result received after database lock) and one G12 (result received after database lock); 
iQ61R according to local laboratory;
jThree Q61R, two Q61L, two Q61K, two Q61, and one G12 mutation according to local laboratory.
kData for clinical activity available for 63 patients for response-rate analysis set (Ascierto, 2013).
DCR, disease control rate; NR, not reported.
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expression postbaseline was observed in 10 of 14 paired 
samples. Median reduction in pERK H-score was 47% 
and 70% in the cytoplasmic and nuclear compartments, 
respectively, and median DUSP6 reduction, in Δ Ct, 
was 36%. MAPK pathway inhibition was shown in 
both responders and nonresponders, with no apparent 
association between reduced expression of either pERK 
or DUSP6 with overall response rates.
Comparison of patients in the BRAF- and NRAS-
mutated arms with TCGA melanoma cases showed overall 
concordance of the tumor genetic landscape with regard to 
the percentage of patients experiencing alterations in the 
most frequently mutated genes (Supplementary Figure 1A 
and 1B). Within the BRAF-mutated group, concordance 
was observed in PTEN, TRRAP, and TP53. Slightly more 
CDKN2A alterations and fewer CDKN2B alterations were 
observed in study patients compared with the cases in the 
TCGA database, possibly due to higher sequencing depth 
and more systematic annotation of variants in this study, 
respectively. Within the NRAS-mutated group, concordance 
was observed in CDKN2A/B, TP53, and NOTCH2. There 
were no trends showing any association between efficacy 
and the subtype of NRAS Q61 mutations (Supplementary 
Figure 2). Supplementary Table 2 provides additional 
context for the BRAF and NRAS mutations, including 
mutation type and presence or absence in the Catalogue 
of Somatic Mutations in Cancer (Supplementary Table 2).
A weak association between specific mutations or 
total number of mutations with either measure of efficacy 
was shown among patients with either BRAF- or NRAS-
mutated melanoma (Figure 2A and 2B, respectively). 
Notable differences between BRAF- and NRAS-mutated 
melanomas at baseline included PTEN (21% vs 2.5% of 
patients, respectively) and P53 (13% vs 22%, respectively). 
Five BRAF-mutated tumors had broad amplifications on 
chromosome 7 and five others on chromosome 1, while 
three NRAS-mutated tumors exhibited amplifications on 
chromosome 11. Amplifications tended to be associated 
with shorter progression-free survival (PFS); for example, 
amplifications in CCND1 or CCND3 occurred only in five 
NRAS-mutated patients with a PFS shorter than the median 
(≤ 3.6 months).  
Beyond individual genes, pathways or coherent 
classes of genes were examined, namely the cell cycle and 
PI3K and P53 pathways as well as epigenetic regulators, 
transcription factors, and DNA damage response genes. 
The rationale for these groupings is that genes with 
parallel or related functions relevant to melanoma may 
harbor mutually exclusive mutations, as is the case for 
BRAF and NRAS, such that they would escape notice when 
examined individually. Among both BRAF- and NRAS-
mutated arms, genetic pathway alterations were observed, 
predominantly within the cell cycle genes (Figure 2A 
and 2B; Supplementary Table 3). Within the BRAF-
mutated group, these alterations were driven primarily by 
CDKN2A, which was altered in 27 of 48 patients (56.3%). 
Among the NRAS-mutated group, 45 of 78 patients (58%) 
had alterations in the cell cycle genes; 27 of 65 patients 
(42%) had both alterations within the cell cycle genes and 
a short PFS (≤ 110 days).  
DISCUSSION
The biomarker analyses of this study aimed to 
describe the biological impact of MEK-targeted inhibition 
of the MAPK pathway with binimetinib, establish the 
BRAF- and NRAS-mutated tumor genetic landscape, and 
explore the link between genetic pathway alterations 
and the response to binimetinib. Understanding the 
biological impact of MEK inhibition, and the predictive 
value of tumor genetic markers and pathway alterations 
on response, could be invaluable for optimizing the 
efficacy of targeted therapy. Pharmacodynamic analyses 
showed MAPK pathway inhibition by binimetinib on 
Day 15 through decreased pERK levels and DUSP6 
gene expression. These decreases were observed in both 
BRAF- and NRAS-mutated arms, and were moderate and 
consistent with observations in other cancer studies with 
MEK inhibitors, such as the observed suppression of 
pERK by cobimetinib (GDC-0973) both in vitro and in 
vivo [32]. However, no association between reduced pERK 
or DUSP6 levels with clinical efficacy was observed, 
likely due to limited data or sampling time points. Another 
consideration is that in certain genomic contexts, including 
some tumors with RAS mutations (ie, preclinical data of 
BRAF/RAS-WT tumor cells) [33], the MEK-ERK pathway 
may not be fundamental for tumor cell proliferation; thus, 
inhibition of the MEK-ERK pathway may not reduce the 
survival of certain tumor cells.
Overall, the tumor genetic landscape for patients 
with BRAF- and NRAS-mutated melanoma was 
concordant with that reported in TCGA melanoma cases. 
This observation demonstrated a consistency of genetic 
alterations in this patient subset with historical samples. 
This equivalence also contributes to the validation of these 
biomarker results, leading toward a better understanding 
of changes that occur within patients with BRAF- and 
NRAS-mutated melanoma and their predictive value. 
Several patients with BRAF-mutated tumors had 
amplification of genes on the long arm of chromosome 
7 (7q); seven patients exhibited MET and/or HGF 
amplifications, with coamplification occurring in three 
of them. Five of these seven patients (including the three 
patients with coamplification) had a PFS that was shorter 
than the median PFS of 3.5 months for the population with 
BRAF mutations. Particular genes of high interest on 7q 
include HGF, MET, EZH2, and SMO. The latter two have 
been associated with driving the progression of melanoma 
[34, 35]; HGF and MET form a functional pair since they 
are cognate ligand and receptor, respectively. Among 
patients in the NRAS-mutated group, CCND1 or CCND3 
amplifications were exclusively seen in five patients with 
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shorter PFS, indicating that constitutive CDK4/6 pathway 
signaling may lead to resistance. In this regard, a phase Ib/
II study (NCT01781572) with binimetinib in combination 
with the CDK4/6 inhibitor ribociclib (LEE011) in patients 
with NRAS-mutant melanoma has recently completed, 
with preliminary data from the initial Phase 1b study 
suggesting a manageable safety profile and favourable 
efficacy [36]. Furthermore, positive phase III data have 
been reported for the NEMO study comparing the 
efficacy of binimetinib single agent versus dacarbazine in 
Figure 2: Genetic landscape of tumor samples and efficacy in patients with (A) BRAF mutationa and (B) NRAS mutation. aThe genetic 
landscape shows gene alterations that occurred in ≥ 3 patients in the BRAF-mutant population; bBlue indicates patients with PFS ≥ 3.5 
months (median PFS in the 45 mg BRAFV600 arm); cBlue indicates patients with reduction in sum of the longest diameter from baseline 
≥ 30%; dRed indicates patients with PFS ≥ 3.6 months (median PFS in the NRAS-mutated arm); eRed indicates patients with reduction in 
sum of the longest diameter from baseline ≥ 30%; *Patients in the BRAF-mutant group receiving binimetinib 60 mg BID who were dose 
reduced to 45 mg BID; *Patients in the BRAF-mutant group receiving binimetinib 60 mg BID who were not dose reduced. MET and HGF 
amplifications in the BRAF panel CCND3 and CCND1 amplifications in the NRAS panel are indicated with a black box. BID, twice daily; 
fs, frameshift; ns, nonsense; PFS, progression-free survival. 
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unresectable or metastatic NRAS-mutant melanoma [22]. 
We cannot rule out other genetic alterations that were 
observed in patients with progressive disease that may 
have had an effect on PFS.
Binimetinib showed activity in patients with BRAF- 
or NRAS-mutated melanoma through MAPK pathway 
inhibition, and genomic profiling highlighted genetic 
alterations of interest that could be used as potential 
predictive biomarkers of response to binimetinib. Although 
all comparisons with patient outcomes for these data are 
currently observational in nature, they are indicative of 
the potential predictive use of genetic data in future larger 
cohorts. Combined with interpretation of biomarker data 
from other ongoing studies of binimetinib, these data 
could provide context toward understanding the biological 
impact of and prediction of response to binimetinib. Of 
relevance, assessment of potential additional biomarkers of 
efficacy or safety was incorporated in the aforementioned 
NEMO trial, in the phase III COLUMBUS trial 
(NCT01909453) comparing binimetinib plus encorafenib 
with encorafenib or vemurafenib in patients with BRAF-
mutated melanoma, and in the phase II LOGIC-2 trial 
(NCT02159066) investigating sequential encorafenib/
binimetinib combination therapy followed by a 
combination with targeted agents after disease progression 
in patients with BRAFV600 -mutated melanoma.
MATERIALS AND METHODS
Patients 
Details of the study have been published previously 
[24]. Briefly, baseline BRAF or NRAS status was assessed 
using archival or fresh tumor biopsies either at a local 
or central laboratory (MolecularMD) and analyzed by 
a semiquantitative polymerase chain reaction (BRAF) 
or bidirectional Sanger sequencing assay (NRAS). After 
patient enrollment, all tumor biopsies assessed at local 
laboratories were sent to the central laboratory for 
mutational status confirmation. 
The study was designed, undertaken, and reported in 
accordance with the Declaration of Helsinki and the ICH 
Harmonised Tripartite Guideline for Good Clinical Practice. 
The protocol was approved by an institutional review 
board, independent ethics committee, or research ethics 
board at each institution. All patients provided written 
informed consent before screening and additional consent 
if participating in the exploratory biomarker analysis.
Study design and treatments
This study was a nonrandomized, open-label phase 
II study in which patients were divided into one of three 
treatment arms according to tumor NRAS or BRAF status: 
binimetinib 45 mg BID or 60 mg BID for BRAF-mutant 
tumors, or binimetinib 45 mg BID for NRAS-mutant 
tumors. The 60 mg BID dose of binimetinib for patients 
with BRAF-mutated tumors was subsequently reduced 
to 45 mg BID per a protocol amendment following two 
serious adverse events (grade 4 acute liver failure in 
1 patient; grade 3 cardiomyopathy, decreased ejection 
fraction and tachycardia in a second patient). Treatment 
was administered in 28-day cycles. Binimetinib was 
administered orally (film-coated tablet) BID from Day 1 
of Cycle 1 and continuously throughout the study.
The primary endpoint was the proportion of patients 
who achieved an objective response (complete response 
+ partial response). Secondary endpoints included PFS, 
time to response, safety, tolerability, pharmacokinetics, 
and pharmacodynamics. Biomarker analyses, the focus 
of this manuscript, were prespecified secondary and 
exploratory objectives, and included: assessment of 
pharmacodynamic effects of binimetinib on MEK/MAPK 
signaling by analysis of pERK and DUSP6 gene expression 
in pre- versus post-dose tumor biopsies; examination 
of correlations between pERK, DUSP6 expression and 
efficacy; assessment of the baseline molecular status of the 
tumors and exploration of potential predictive biomarkers 
of response to binimetinib.
Study procedures
Safety and pharmacokinetic assessments and 
overall efficacy data from an earlier cut-off were reported 
previously [24]. Biomarker-related efficacy data are 
presented here. A whole blood sample (~6.0 mL) was 
taken from all patients (at Cycle 1 Day 1) to provide a 
non-tumorous tissue sample to perform genetic analysis 
(if compliant with local IRB requirements) This sample 
was analyzed to compare tumor-specific gene alterations 
in DNA from tumor samples with DNA from normal-
non-tumor cells.  Baseline and on-study (Cycle 1, Day 
15) fresh tumor biopsy samples were collected from 
patients in all three treatment arms and analyzed for 
the pharmacodynamic markers pERK and DUSP6. 
Immunohistochemistry (IHC) data reported from the lab 
included quantitative data (eg, percent tumor and percent 
positive cells) or a semi quantitative measure of protein 
expression reported as 3 individual components, 1+ 2+ 
and 3+. The pathologist determined whether the staining 
in a cellular compartment was absent (0+), slight (1+), 
moderate (2+), or strong (3+). The H-Score used to assess 
pERK for each cellular compartment was then calculated 
as the sum of (the percentages of stained cells * their 
intensity), or (%1+) + (2 * %2+) + (3 * %3+) and ranged 
between 0 and 300. Δ Ct (cycle threshold), a relative 
measure of the concentration of target in the PCR reaction, 
was used to measure DUSP-6. Δ Ct is the normalization 
of Raw Ct that is calculated by subtracting the baseline 
(reference sample): (Δ Ct = Ct Gene of interest – Ct 
Internal control). Deep sequencing of formalin-fixed, 
paraffin-embedded tumor samples from enrolled patients 
Oncotarget1857www.oncotarget.com
was used to profile genomic alterations in 296 cancer-
related genes in order to identify potential predictive 
markers of binimetinib sensitivity, as previously described 
[30]. Briefly, DNA was sequenced at high depth (median 
744X) on an Illumina HiSeq 2500 sequencer following 
probe-based targeted exome capture. 
Analyses were descriptive and exploratory in nature, 
and no inferential analysis was performed. Data were 
summarized with respect to demographic and baseline 
characteristics and all relevant pharmacodynamics and 
genetic alteration measurements.  
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